HUMAN Shared Data Model Clause Samples

HUMAN Shared Data Model. The scope of the HUMAN Shared Data Model (SDM) is the representation of the factory from a worker centric perspective meant to achieve an integrated and holistic view of the worker-factory pair. This holistic view will enable to reason considering the whole picture to envision interventions aiming to harmonize workers’ activities with factory behavior both in the short- and long-term. An overall picture of the data model is shown in Figure 1. The presented model can be logically divided in 4 distinct areas. The first area, with the blue background classes, is the representation of the worker. The second area, with the pink background classes, represents the factory related elements. The third area, with the green background classes, is the design of jobs, task and their scheduling. Last but not least, the area with orange background classes, is the formalization of the events that happens to the actors inside the system. Classes in red are common parts between two or more parts of the data model, like Trait and Measure. In the rest of this section we are going to explain, for each of the data model logical segments, the rationale that has driven the modeling and to provide a detailed description of the classes, pointing out which are the fields and the relations to the other classes in the system.
View Source

Related to HUMAN Shared Data Model

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • How to File an Appeal of a Prescription Drug Denial For denials of a prescription drug claim based on our determination that the service was not medically necessary or appropriate, or that the service was experimental or investigational, you may request an appeal without first submitting a request for reconsideration. You or your physician may file a written or verbal prescription drug appeal with our pharmacy benefits manager (PBM). The prescription drug appeal must be submitted to us within one hundred and eighty (180) calendar days of the initial determination letter. You will receive written notification of our determination within thirty (30) calendar days from the receipt of your appeal. Your appeal may require immediate action if a delay in treatment could seriously jeopardize your health or your ability to regain maximum function, or would cause you severe pain. To request an expedited appeal of a denial related to services that have not yet been rendered (a preauthorization review) or for on-going services (a concurrent review), you or your healthcare provider should call: • our Grievance and Appeals Unit; or • our pharmacy benefits manager for a prescription drug appeal. Please see Section 9 for contact information. You will be notified of our decision no later than seventy-two (72) hours after our receipt of the request. You may not request an expedited review of covered healthcare services already received.

  • Required Procurement Procedures for Obtaining Goods and Services The Grantee shall provide maximum open competition when procuring goods and services related to the grant- assisted project in accordance with Section 287.057, Florida Statutes.

  • Data Loss Prevention DST shall implement a data leakage program that is designed to identify, detect, monitor and document Fund Data leaving DST’s control without authorization in place.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.